טוען...
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...
שמור ב:
| הוצא לאור ב: | J Microbiol Immunol Infect |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7156211/ https://ncbi.nlm.nih.gov/pubmed/32205092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jmii.2020.03.005 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|